New biochemical markers: from bench to bedside.

[1]  M. Wolzt,et al.  Asymmetric Dimethylarginine Predicts Major Adverse Cardiovascular Events in Patients With Advanced Peripheral Artery Disease , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[2]  Redefinition of myocardial infarction: new challenges and opportunities. , 2006, European heart journal.

[3]  R. Califf,et al.  Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. , 2006, Journal of the American College of Cardiology.

[4]  H. Tunstall-Pedoe,et al.  Redefinition of Myocardial Infarction: Prospective Evaluation in the Community , 2006, Circulation.

[5]  Fred S Apple,et al.  Biomarkers in acute cardiac disease: the present and the future. , 2006, Journal of the American College of Cardiology.

[6]  R. Vasan,et al.  Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations , 2006, Circulation.

[7]  Steven V. Ley,et al.  Targeting C-reactive protein for the treatment of cardiovascular disease , 2006, Nature.

[8]  W. Markiewicz,et al.  Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. , 2006, Journal of the American College of Cardiology.

[9]  K. Eagle,et al.  The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). , 2006, American heart journal.

[10]  R. Böger.  Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond , 2006, Annals of medicine.

[11]  S. Iliceto,et al.  Analytical and clinical evaluation of a new heart-type fatty acid-binding protein automated assay , 2006, Clinical chemistry and laboratory medicine.

[12]  Fred S Apple,et al.  Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. , 2005, Clinical chemistry.

[13]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[14]  P. Libby,et al.  CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. , 2004, Circulation.

[15]  L. Biasucci.  CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice Clinical Use of Inflammatory Markers in Patients With Cardiovascular Diseases A Background Paper , 2004, Circulation.

[16]  George A Mensah,et al.  CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: overview. , 2004, Circulation.

[17]  P. Wilson,et al.  CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. , 2004, Circulation.

[18]  B. Lindahl,et al.  Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. , 2004, American heart journal.

[19]  A. Jaffe,et al.  Acute coronary syndrome biomarkers: the need for more adequate reporting. , 2004, Circulation.

[20]  M. Emdin,et al.  Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. , 2004, Clinical chemistry.

[21]  C. Zoccali,et al.  ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. , 2003, Atherosclerosis. Supplements.

[22]  Antonio Colombo,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. , 2003, Circulation.

[23]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[24]  P. Libby,et al.  Soluble CD40L: Risk Prediction After Acute Coronary Syndromes , 2003, Circulation.

[25]  S. Honda,et al.  Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. , 2003, Clinical chemistry.

[26]  Patrick André,et al.  Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. , 2002, Circulation.

[27]  P. Libby,et al.  CD40 Signaling and Plaque Instability , 2001, Circulation research.

[28]  A. Wu,et al.  Quality Specifications for Cardiac Troponin Assays , 2001, Clinical chemistry and laboratory medicine.

[29]  K. Thygesen,et al.  Erratum: Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction (Journal of the American College of Cardiology (2000) 36 (959-969)) , 2001 .

[30]  D. Bar-Or,et al.  A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. , 2000, The Journal of emergency medicine.

[31]  Hugo A. Katus,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.

[32]  K. Forfang,et al.  Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. , 1999, Circulation.

[33]  M. Plebani,et al.  Cardiac markers: present and future , 1999, International journal of clinical & laboratory research.